严重的胰岛素抵抗:诊断和管理
Yu-Lan Wu1, Xin Wang1, Wei-Wei Zhang2
1Department of Endocrinology, People's Hospital of Pengshui County, Pengshui, 409600, China.
Current diabetes reviews
|September 19, 2025
概括
严重的胰岛素抵抗,一组罕见的内分泌疾病,提出独特的挑战,与普通的胰岛素抵抗不同. 早期识别和量身定制的治疗对于改善患者的治疗结果至关重要.
科学领域:
- 内分泌学 在内分泌学.
- 代谢障碍 代谢障碍 代谢障碍
- 遗传学 是一个遗传学.
背景情况:
- 胰岛素抵抗与糖尿病,代谢综合征,心血管疾病和癌症有关.
- 严重的胰岛素耐药性包括罕见的高血糖和高胰岛素血症疾病,往往被误诊.
- 现有的文献缺乏严重胰岛素耐药性的全面总结.
研究的目的:
- 提供严重胰岛素抵抗综合征的详细概述.
- 根据胰岛素信号缺陷位置对这些综合征进行分类.
- 帮助医生进行早期诊断和个性化患者治疗.
主要方法:
- 关于严重胰岛素抵抗病例和综合征的文献综述.
- 基于前受体,受体和后受体胰岛素信号缺陷的分类.
- 原因,临床症状,诊断和治疗策略的总结.
主要成果:
- 确定了三种主要类型的严重胰岛素抵抗:前受体 (例如,胰岛素自身免疫综合征),受体水平 (A型,B型) 和后受体 (例如,脂质变).
- 详细介绍了每个类型的不同临床表现,诊断标准和治疗方法.
- 突出了导致潜在误诊的复杂性和稀有性,作为常见的糖尿病.
结论:
- 严重的胰岛素抵抗需要特定的诊断和管理策略,与常见的胰岛素抵抗不同.
- 了解信号缺陷的分子基础是准确诊断的关键.
- 及时和个性化的治疗可以显著改善这些罕见疾病患者的临床结果.
相关概念视频
Diabetes: Management and Pharmacotherapy
868
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
868
Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
Insulin: Dosing Regimen and Adverse Effects
689
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
689
Diabetes: Symptoms, Diagnosis, and Complications
2.1K
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.1K
Diabetes Mellitus: Overview and Type I Subtype
4.9K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.9K
Oral Hypoglycemic Agents: Biguanides and Glitazones
587
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
587


